Efficacy and Safety of Topical 0.5% Ivermectin Lotion for the Treatment of Head Lice Infestation in Filipinos

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial On The Efficacy And Safety Of Topical 0.5% Ivermectin Lotion For The Treatment Of Head Lice Infestation Among Filipino Children Age 3 Years Or Older

This is a randomized, double-blind, placebo-controlled clinical study evaluating the efficacy and safety of a single application of 0.5% ivermectin lotion in Filipino subjects with head lice.

Study Overview

• Status: Completed
• Conditions: Pediculosis Capitis
• Intervention / Treatment: Drug: 0.5% Ivermectin lotion; Drug: Vehicle

• Study Type: Interventional
• Enrollment (Actual): 120
• Phase: Phase 2

Contacts and Locations

Study Locations

• Philippines
  • Muntinlupa, Philippines
    • Clinical Trial Management and Testing Associates, Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 3 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Index subjects must have an active lice infestation defined as: At least 3 live lice (adult and/or nymphs) present on the scalp and/or hair as determined by a trained evaluator; After the index subject has been enrolled, additional infested household members will be enrolled.
• Household subjects must have an active head lice infestation defined as: At least 1 live louse (adult and /or nymph) present on the scalp and/or hair, as determined by a trained evaluator (with the exception of the male head of household who may self- assess, as being lice free).
• Subject is male or female;
• Subject is at least 3 years old or older at the time of enrollment;
• Subject is in good general health based on the medical history;
• Each adult subject must have an appropriately signed Informed Consent agreement. For children, parents/guardian must sign an Informed Parental Consent agreement for children not old enough to do so. Children of a specified age will be administered a child's assent form
• The caregiver of a subject must be willing to allow all household members to be screened for head lice. If other household members are found to have an active head lice infestation, they must be willing and able to participate in the study. No more than one working male per household maybe excluded from evaluation if he is assessed as being lice free by himself or the caregiver and cannot come in due to his work schedule. If this individual may have lice, he must come to the test facility, otherwise the entire household will be excluded from study participation.
• Subject and/or caregiver must be physically able and willing to report to the testing center for the supervised application of the product.
• Subjects agrees not to use any other form of lice treatment (commercial or mechanical/manual) while participating in the study;
• Following application and rinsing of the test product, subject agrees not to shampoo / wash, or rinse their hair or scalp until the 24-hour post treatment evaluation has been completed;
• Subject agrees to not cut or chemically treat their hair while participating in the study;
• Subject agrees to follow all study instructions.

Exclusion Criteria:

• History of irritation or sensitivity to ivermectin or lotion components pediculosis or hair care products;
• Presence of visible skin / scalp conditions that are not attributable to head lice infestation, such as erythema, blisters, vesicles which in the opinion of the investigative personnel will interfere with safety and / or efficacy evaluations;
• Subjects suffering from psoriasis, atopic dermatitis or other conditions, which in the opinion of the investigator may compromise the objective of the study;
• Treatment for head lice (OTC, home remedy or Rx) in the last 14 days;
• Subjects under treatment which in the opinion of the investigator will interfere with the study results;
• Subjects who participated in a previous investigational drug study within the past 30 days;
• Subjects who does not understand the requirements for the study participation and/ or likely exhibit poor compliance, in the opinion of the investigator;
• Females who are pregnant or lactating.
• Living in a household where at least one member is pregnant, lactating, or planning a pregnancy
• Subjects with skin lesions, specifically skin breaks are excluded because of possible absorption of the drug

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Vehicle control	Drug: Vehicle; The intervention is composed of a single application of the vehicle control.
Experimental: 0.5% Ivermectin Lotion	Drug: 0.5% Ivermectin lotion; The intervention is composed of a single application of the 0.5% ivermectin lotion.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Proportion of participants cured of head lice infestation from their assigned product on day 2, day 8 and day 15 after the first treatment.	Day 2 to day 15 after product application

Collaborators and Investigators

• Sponsor: United Laboratories
• Investigators: Principal Investigator: Gertrude Chan, M.D., Clinical Trial Management and Testing Associates, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): September 14, 2017
• Primary Completion (Actual): October 12, 2017
• Study Completion (Actual): November 9, 2017

Study Registration Dates

• First Submitted: September 14, 2017
• First Submitted That Met QC Criteria: September 15, 2017
• First Posted (Actual): September 18, 2017

Study Record Updates

• Last Update Posted (Actual): March 7, 2018
• Last Update Submitted That Met QC Criteria: March 5, 2018
• Last Verified: March 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Infections; Parasitic Diseases; Ectoparasitic Infestations; Skin Diseases, Parasitic; Skin Diseases, Infectious; Lice Infestations; Anti-Infective Agents; Antiparasitic Agents; Ivermectin
• Other Study ID Numbers: RD2017-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No